Qiagen back in black after acquisitions

Netherlands-based Qiagen has returned to profit for the third quarter of the year, after falling into loss on acquisition charges in the same period of the year before.

Turnover increased 31% to $230.8 million, boosted by additional revenue from recently-acquired subsidiaries Corbett Life Sciences, Digene and eGene. R&D investment was up 35% to 24.1 million.

Net income reached $20.8 million from a loss of $7.3 million. At the end of the period, the firm had $326.0 million in cash and cash equivalents, down 6% from the end of last year.